RGD Reference Report - Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations.

Authors: Shenkar, Robert  Shi, Changbin  Rebeiz, Tania  Stockton, Rebecca A  McDonald, David A  Mikati, Abdul Ghani  Zhang, Lingjiao  Austin, Cecilia  Akers, Amy L  Gallione, Carol J  Rorrer, Autumn  Gunel, Murat  Min, Wang  De Souza, Jorge Marcondes  Lee, Connie  Marchuk, Douglas A  Awad, Issam A 
Citation: Shenkar R, etal., Genet Med. 2015 Mar;17(3):188-196. doi: 10.1038/gim.2014.97. Epub 2014 Aug 14.
RGD ID: 401827114
Pubmed: PMID:25122144   (View Abstract at PubMed)
PMCID: PMC4329119   (View Article at PubMed Central)
DOI: DOI:10.1038/gim.2014.97   (Journal Full-text)


PURPOSE: The phenotypic manifestations of cerebral cavernous malformation disease caused by rare PDCD10 mutations have not been systematically examined, and a mechanistic link to Rho kinase-mediated hyperpermeability, a potential therapeutic target, has not been established.
METHODS: We analyzed PDCD10 small interfering RNA-treated endothelial cells for stress fibers, Rho kinase activity, and permeability. Rho kinase activity was assessed in cerebral cavernous malformation lesions. Brain permeability and cerebral cavernous malformation lesion burden were quantified, and clinical manifestations were assessed in prospectively enrolled subjects with PDCD10 mutations.
RESULTS: We determined that PDCD10 protein suppresses endothelial stress fibers, Rho kinase activity, and permeability in vitro. Pdcd10 heterozygous mice have greater lesion burden than other Ccm genotypes. We demonstrated robust Rho kinase activity in murine and human cerebral cavernous malformation vasculature and increased brain vascular permeability in humans with PDCD10 mutation. Clinical phenotype is exceptionally aggressive compared with the more common KRIT1 and CCM2 familial and sporadic cerebral cavernous malformation, with greater lesion burden and more frequent hemorrhages earlier in life. We first report other phenotypic features, including scoliosis, cognitive disability, and skin lesions, unrelated to lesion burden or bleeding.
CONCLUSION: These findings define a unique cerebral cavernous malformation disease with exceptional aggressiveness, and they inform preclinical therapeutic testing, clinical counseling, and the design of trials.Genet Med 17 3, 188-196.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
PDCD10Humancerebral cavernous malformation 3 exacerbatesIAGP DNA:mutations:multiple (human)RGD 
Pdcd10Ratcerebral cavernous malformation 3 exacerbatesISOPDCD10 (Homo sapiens)DNA:mutations:multiple (human)RGD 
Pdcd10Mousecerebral cavernous malformation 3 exacerbatesISOPDCD10 (Homo sapiens)DNA:mutations:multiple (human)RGD 

Phenotype Annotations    Click to see Annotation Detail View

Manual Human Phenotype Annotations - RGD

Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
PDCD10HumanCerebral cavernous malformation exacerbatesIAGP DNA:mutations:multipleRGD 
Objects Annotated

Genes (Rattus norvegicus)
Pdcd10  (programmed cell death 10)

Genes (Mus musculus)
Pdcd10  (programmed cell death 10)

Genes (Homo sapiens)
PDCD10  (programmed cell death 10)


Additional Information